Trigemina, Inc.
Trigemina, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Trigemina, Inc..
Trigemina, Inc. is a company.
Key people at Trigemina, Inc..
Trigemina, Inc. is a biotechnology company specializing in the development of non-opioid neurological therapies aimed at treating chronic migraine and neuropathic pain. Their core product focus is on innovative drug formulations and delivery systems, particularly intranasal delivery of analgesic peptides targeting the trigeminal nerves, which are central to head and facial pain. This approach seeks to provide effective pain relief without the risks associated with opioid treatments. Trigemina serves patients suffering from chronic migraine and other neuropathic pain conditions, addressing a significant unmet medical need with novel, targeted therapies. The company has demonstrated growth momentum through multiple funding rounds totaling over $23 million and ongoing clinical development efforts[1][2][3].
Founded in 2006 and headquartered in Moraga, California, Trigemina was co-founded by Martin Angst, with leadership including Chief Medical Officer Shashidhar Kori. The company emerged from the recognition that migraine and neuropathic pain are debilitating conditions with limited effective non-opioid treatments. Trigemina pioneered the intranasal delivery of antinociceptive peptides, leveraging the unique pathway to the trigeminal ganglia to bypass traditional barriers like the blood-brain barrier and gastrointestinal filters. Early traction included securing SBIR funding and presenting clinical data demonstrating the potential benefits of activating oxytocin receptors for migraine relief, marking pivotal moments in validating their therapeutic approach[2][3].
Trigemina rides the growing trend toward safer, non-addictive pain management solutions amid increasing regulatory and societal pressure to reduce opioid use. The timing is critical as chronic migraine affects millions globally, with high economic and quality-of-life costs. Advances in peptide therapeutics and targeted delivery systems position Trigemina to influence the broader pharmaceutical and biotech ecosystem by demonstrating the viability of intranasal peptide delivery for neurological conditions. Their work contributes to expanding the therapeutic arsenal for pain management and may catalyze further innovation in non-opioid analgesics[1][3].
Looking ahead, Trigemina is poised to advance its clinical programs and potentially bring first-in-class non-opioid migraine treatments to market. Trends such as increased demand for safer pain therapies, advances in peptide drug design, and regulatory support for opioid alternatives will shape their trajectory. Their influence may grow as they validate their delivery platform and expand indications beyond migraine to other neuropathic pain disorders. Continued funding and successful clinical outcomes will be key to scaling their impact in the healthcare sector, potentially transforming chronic pain treatment paradigms. This aligns with their foundational mission to provide innovative, effective, and safer neurological therapies[1][2][3][4].
Key people at Trigemina, Inc..
